Novartis AG ADR (NVS)vsEnvista Holdings Corp (NVST)
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
NVST
Envista Holdings Corp
$27.78
-2.08%
HEALTHCARE · Cap: $4.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1919% more annual revenue ($56.69B vs $2.81B). NVS leads profitability with a 22.5% profit margin vs 2.4%. NVS trades at a lower P/E of 22.0x. NVST earns a higher WallStSmart Score of 54/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NVST
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for NVST.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 130.0% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
ROE of 2.2% — below average capital efficiency
2.4% margin — thin
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : NVST
The strongest argument for NVST centers on Price/Book, EPS Growth. Revenue growth of 14.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NVST
The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 64.8x leaves little room for execution misses. Thin 2.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVST carries more volatility with a beta of 0.86 — expect wider price swings.
NVST is growing revenue faster at 14.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVST scores higher overall (54/100 vs 51/100) and 14.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Envista Holdings Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?